Posted by Michael Wonder on 13 Sep 2024
Dupixent (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic oesophagitis
12 September 2024 - This is the ninth indication for Dupixent in Canada and its second in gastroenterology.
Health Canada has issued a notice of compliance for Dupixent (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic oesophagitis. This approval expands the initial Health Canada notice of compliance for eosinophilic oesophagitis in May 2023 for patients aged 12 years and older, weighing at least 40 kg.
